Literature DB >> 21054398

Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives.

Partha Pratim Roy1, Kunal Roy.   

Abstract

OBJECTIVES: Aromatase (CYP19) inhibitors have emerged as promising candidates for the treatment of estrogen-dependent breast cancer. In this study, a series of androstenedione derivatives with CYP19 inhibitory activity was subjected to a molecular docking study followed by quantitative structure-activity relationship (QSAR) analyses in search of ideal physicochemical characteristics of potential aromatase inhibitors.
METHODS: The QSAR studies were carried out using both two-dimensional (topological, and structural) and three-dimensional (spatial) descriptors. We also used thermodynamic parameters along with 2D and 3D descriptors. Genetic function approximation (GFA) and genetic partial least squares (G/PLS) were used as chemometric tools for QSAR modelling. KEY
FINDINGS: The docking study indicated that the important interacting amino acids in the active site were Met374, Arg115, Ile133, Ala306, Thr310, Asp309, Val370, Leu477 and Ser478. The 17-keto oxygen of the ligands is responsible for the formation of a hydrogen bond with Met374 and the remaining parts of the molecules are stabilized by the hydrophobic interactions with the non-polar amino acids. The C2 and C19 positions in the ligands are important for maintaining the appropriate orientation of the molecules in the active site. The results of docking experiments and QSAR studies supported each other.
CONCLUSIONS: The developed QSAR models indicated the importance of some Jurs parameters, structural parameters, topological branching index and E-state indices of different fragments. All the developed QSAR models were statistically significant according to the internal and external validation parameters.
© 2010 The Authors. JPP © 2010 Royal Pharmaceutical Society of Great Britain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054398     DOI: 10.1111/j.2042-7158.2010.01154.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

2.  Molecular modeling on structure-function analysis of human progesterone receptor modulators.

Authors:  Ria Pal; Md Ataul Islam; Tabassum Hossain; Achintya Saha
Journal:  Sci Pharm       Date:  2011-06-30

3.  Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.

Authors:  Joshua J Ziarek; Yan Liu; Emmanuel Smith; Guolin Zhang; Francis C Peterson; Jun Chen; Yongping Yu; Yu Chen; Brian F Volkman; Rongshi Li
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  Quantum mechanical/molecular mechanical and docking study of the novel analogues based on hybridization of common pharmacophores as potential anti-breast cancer agents.

Authors:  Parvin Asadi; Ghadamali Khodarahmi; Hossein Farrokhpour; Farshid Hassanzadeh; Lotfollah Saghaei
Journal:  Res Pharm Sci       Date:  2017-06

Review 5.  Towards understanding aromatase inhibitory activity via QSAR modeling.

Authors:  Watshara Shoombuatong; Nalini Schaduangrat; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2018-07-20       Impact factor: 4.068

6.  3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.

Authors:  Sehan Lee; Mace G Barron
Journal:  J Cheminform       Date:  2018-01-18       Impact factor: 5.514

7.  One-pot Fluorination and Organocatalytic Robinson Annulation for Asymmetric Synthesis of Mono- and Difluorinated Cyclohexenones.

Authors:  Xin Huang; Weizhao Zhao; Xiaofeng Zhang; Miao Liu; Stanley N S Vasconcelos; Wei Zhang
Journal:  Molecules       Date:  2018-09-04       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.